

Attorney Docket No.: MCP-0141
Inventors: Halpern and England
Serial No.: 09/744,406
Filing Date: January 22, 2001
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1-39 (canceled)

Claim 40: (currently amended) A cellular immunogen for ~~immunizing a host against the effects of the product of a target proto oncogene, the overexpression of which target proto oncogene is associated with a cancer which promotes tumor regression in a host, said cellular immunogen comprising cells which are allogeneic with respect to the host, said allogeneic cells having been transfected with at least one vector comprising at least one non-transforming transgene cognate to the a target proto-oncogene, said non-transforming cognate transgene derived by deletion of a sequence of the transgene essential for transformation and consisting of wild-type sequence outside the deleted sequence, and a strong promoter to drive the expression of the cognate transgene in the transfected cells, wherein the non transforming cognate transgene encodes a gene product which induces host immunoreactivity to host self determinants of the product of the target proto-oncogene gene and the target proto-oncogene is selected from the group consisting of and the target proto-oncogene is selected from the group consisting of AKT-2, c-erbB-2 (HER2/neu), MDM-2, c-myc, c-myb, c-ras, c-src and c-yes.~~

Attorney Docket No.: MCP-0141
Inventors: Halpern and England
Serial No.: 09/744,406
Filing Date: January 22, 2001
Page 4

Claim 41: (currently amended) A method for preparing a cellular immunogen ~~for immunizing a host against the effects of the product of a target proto-oncogene, the overexpression of which target proto-oncogene is associated with a cancer which promotes tumor regression in a host,~~ the method comprising:

transfected cells which are allogeneic with respect to the host with at least one vector comprising at least one non-transforming transgene cognate to the target proto-oncogene, said non-transforming cognate transgene derived by deletion of a sequence of the transgene essential for transformation and consisting of wild-type sequence outside the deleted sequence, and a strong promoter to drive the expression of the non-transforming cognate transgene in the transfected cells, wherein ~~the non-transforming cognate transgene encodes a gene product which induces host immunoreactivity to host self-determinants of the product of the target proto-oncogene gene and the target proto-oncogene is selected from the group consisting of AKT-2, c-erbB-2 (HER2/neu), MDM-2, c-myc, c-myb, c-ras, c-src and c-yes.~~

Claim 42: (currently amended) A cellular immunogen ~~for immunizing a host against the effects of the product of a target proto-oncogene, the overexpression of which target proto-oncogene is associated with a cancer which promotes tumor regression in a host,~~ said cellular immunogen

Attorney Docket No.: MCP-0141
Inventors: Halpern and England
Serial No.: 09/744,406
Filing Date: January 22, 2001
Page 5

comprising cells which are allogeneic with respect to the host, said allogeneic cells having been transfected with at least one vector comprising at least one non-transforming transgene cognate to ~~the a~~ target proto-oncogene, said non-transforming cognate transgene derived by deletion of a sequence of the transgene essential for transformation and consisting of wild-type sequence outside the deleted sequence, and a strong promoter to drive the expression of the cognate transgene in the transfected cells, wherein ~~the non-transforming cognate transgene encodes a gene product which induces host immunoreactivity to host self determinants of the product of the target proto oncogene gene and the target proto-oncogene is selected from the group consisting of c-erbB-2 (HER2/neu), c-myc and c-src.~~

Claim 43: (currently amended) A method for preparing a cellular immunogen ~~for immunizing a host against the effects of the product of a target proto oncogene, the overexpression of which target proto oncogene is associated with a cancer which promotes tumor regression in a host,~~ the method comprising:

transfected cells which are allogeneic with respect to the host with at least one vector comprising at least one non-transforming transgene cognate to ~~the a~~ target proto-oncogene, said non-transforming cognate transgene derived by deletion of a sequence of the transgene essential for

Attorney Docket No.: MCP-0141
Inventors: Halpern and England
Serial No.: 09/744,406
Filing Date: January 22, 2001
Page 6

transformation and consisting of wild-type sequence outside the deleted sequence, and a strong promoter to drive the expression of the non-transforming cognate transgene in the transfected cells, wherein the non-transforming cognate transgene encodes a gene product which induces host immunoreactivity to host self determinants of the product of the target proto-oncogene gene and the target proto-oncogene is selected from the group consisting of *c-erbB-2* (HER2/neu), *c-myc* and *c-src*.